- Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation2006 | Second Faculty of Medicine
- Imatinib mesylate in the palliative treatment of patients with advanced gastrointestinal stromal tumor2012 | Publication without faculty affiliation
- Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting2019 | Publication without faculty affiliation
- Vliv terapie interferonem- A imatinib mesylátem na vybrané imunologické parametry u pacientů s chronickou myeloidní leukémiíPublication without faculty affiliation
- Angiogenic activators in patients with chronic myeloid leukemia : effect of treatment with imatinib mesylatePublication without faculty affiliation
- Imatinib mesylate (Glivec) in treatment of chronic myeloid leukemia in chronic phase2004 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Cytogenetic clonal evolution in chronic myeloid leukemia during Imatinib mesylate treatmentPublication without faculty affiliation
- The Kinetics of BCR-ABL Transcript Levels in CML Patients in Chronic ar Accelerated Phase during Imatinib Mesylate TreatmentPublication without faculty affiliation
- Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results +12009 | Publication without faculty affiliation
- Comparison of cytogenetic and molecular genetic methods in patients in chronic phase of chronic myeloid leukemia (CML) treated with imatinibe mesylatePublication without faculty affiliation
- Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with Imatinib mesylate for chronic or accelerated disease phase2004 | Publication without faculty affiliation
- Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia2017 | Faculty of Science
- Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells2023 | Central Library of Charles University, Faculty of Science
- Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (BGFG) and soluble endoglin (SCD105) in patients with chronic myeloid leukemia: impact of treatment with imatinib mesylate +1Publication without faculty affiliation
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts2012 | Second Faculty of Medicine
- Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target2016 | First Faculty of Medicine, Faculty of Science
- Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment2010 | Second Faculty of Medicine
- Congenital Dermatofibrosarcoma Protuberans2016 | First Faculty of Medicine
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia2018 | First Faculty of Medicine, Central Library of Charles University
- Gastrointestinal Stromal Tumors (GIST): A Single Center Experience2012 | Third Faculty of Medicine
- Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib2021 | First Faculty of Medicine, Central Library of Charles University, Faculty of Science
- Prognosis of pediatric patients transplanted for Ph plus chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic2008 | First Faculty of Medicine
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up2018 | Publication without faculty affiliation
- An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia2017 | First Faculty of Medicine, Second Faculty of Medicine
- GIST: Current knowledge and treatment modalities2012 | Faculty of Medicine in Hradec Králové
- Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications2013 | Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Discontinuation of biological therapy with tyrosine kinase inhibitors in chronic myeloid leukemia patients2014 | Faculty of Medicine in Pilsen
- Acute Leukemias with ETV6/ABL1 (TEL/ABL) Fusion: Poor Prognosis and Prenatal Origin2010 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine